DOCSLIB.ORG

1 Molecular Physiology and Pathophysiology of Bilirubin Handling by the Blood, Liver

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Molecular Physiology and Pathophysiology of Bilirubin Handling by the Blood, Liver 1 1 MOLECULAR PHYSIOLOGY AND PATHOPHYSIOLOGY OF BILIRUBIN HANDLING BY THE BLOOD, LIVER, 2 INTESTINE, AND BRAIN IN THE NEWBORN 3 THOR W.R. HANSEN1, RONALD J. WONG2, DAVID K. STEVENSON2 4 1Division of Paediatric and Adolescent Medicine, Institute of Clinical Medicine, Faculty of Medicine, 5 University of Oslo, Norway 6 2Department of Pediatrics, Stanford University School of Medicine, Stanford CA, USA 7 __________________________________________________________________________________ 8 2 9 I. Introduction 10 II. Bilirubin in the Body 11 A. Bilirubin Chemistry 12 1. Bilirubin structure 13 2. Bilirubin solubility 14 3. Bilirubin isomers 15 4. Heme degradation 16 5. Biliverdin and biliverdin reductase (BVR) 17 B. Bilirubin as an Antioxidant 18 C. Bilirubin as a Toxin 19 1. Bilirubin effects on enzyme activity 20 2. Toxicity of bilirubin conjugates and isomers 21 D. Other Functions/Roles 22 1. Drug displacement by bilirubin 23 2. Bilirubin interactions with the immune system and 24 inflammatory/infectious mechanisms 25 III. The Production of Bilirubin in the Body 26 A. Heme Catabolism and Its Regulation 27 1. Genetic variants in bilirubin production 28 B. The Effect of Hemolysis 29 1. Disorders associated with increased bilirubin production 30 IV. Bilirubin Binding and Transport in Blood 31 V. Bilirubin in the Liver 32 A. Hepatocellular Uptake and Intracellular Processing 33 B. Bilirubin Conjugation 34 1. Genetic variants in bilirubin conjugation 3 35 a. Crigler-Najjar syndrome type I 36 b. Crigler-Najjar syndrome type II 37 c. Gilbert syndrome 38 2. Genetic variants in transporter proteins 39 C. Bilirubin Excretion 40 VI. Bilirubin in the Intestines 41 A. Excretion into the Intestine 42 B. Role/Function of Bilirubin in Intestines 43 C. Re-Uptake/Enterohepatic Circulation of Bilirubin 44 1. Breast milk jaundice 45 2. Effects of perturbed intestinal transit 46 D. Metabolism of Bilirubin in the Intestine 47 E. Fecal Excretion 48 VII. Bilirubin in the Brain 49 A. History and Clinical Picture of Kernicterus 50 B. The role of the BBB 51 1. Permeability and its modulation 52 2. Transport mechanisms 53 a. The role of ‘flippases’ 54 b. Other BBB molecules with relevance for brain B uptake and excretion 55 C. Brain Blood Flow 56 D. Excretion 57 1. The CSF “sink” 58 2. The BBB 59 E. Bilirubin Metabolism in the Brain 60 F. Regional and Subcellular Localization 4 61 G. Mechanism(s) of Bilirubin Neurotoxicity 62 1. Transient versus permanent effects 63 2. Inhibition of cell respiration 64 3. Membrane effects 65 4. Neurotransmitter metabolism 66 5. Enzyme induction 67 6. Apoptosis and necrosis 68 7. Cell metabolism 69 8. Infection and immunology 70 9. Differential sensitivity 71 10. Neuroprotection 72 11. Hemolysis 73 12. Bilirubin binding 74 13. A common mechanism? 75 14. A note of caution 76 __________________________________________________________________________________ 77 5 78 Hansen TWR, Wong RJ, Stevenson DK. Molecular Physiology and Pathophysiology of Bilirubin 79 Handling by the Blood, Liver, Intestine, and Brain in the Newborn. Physiol Rev XX: XX, 2020. – 80 Bilirubin is the end-product of heme catabolism formed during a process that involves oxidation- 81 reduction reactions and conserves iron body stores. Unconjugated hyperbilirubinemia is common in 82 newborn infants, but rare later in life. The basic physiology of bilirubin metabolism, such as 83 production, transport, and excretion, has been well described. However, in the neonate numerous 84 variables related to nutrition, ethnicity, and genetic variants at several metabolic steps may be 85 superimposed on the normal physiologic hyperbilirubinemia that occurs in the first week of life and 86 results in bilirubin levels that may be toxic to the brain. Bilirubin exists in several isomeric forms that 87 differ in their polarities and is considered a physiologically important antioxidant. Here we review the 88 chemistry of the bilirubin molecule and its metabolism in the body with a particular focus on the 89 processes that impact the newborn infant, and how differences relative to older children and adults 90 contribute to the risk of developing both acute and long-term, neurologic sequelae in the newborn 91 infant. The final section deals with the interplay between the brain and bilirubin, and its entry, 92 clearance, and accumulation. We conclude with a discussion of the current state of knowledge 93 regarding the mechanism(s) of bilirubin neurotoxicity. 6 94 I. INTRODUCTION 95 Among the many transitional processes that take place in newborn infants, jaundice is arguably the 96 most visible, and also the most common cause for diagnostic and therapeutic intervention during the 97 first days of life (306, 329, 440, 491, 627). Neonatal jaundice (NNJ) is caused by the accumulation of 98 unconjugated bilirubin (UCB) in blood and tissues. The normal physiology of bilirubin production, 99 transport, and excretion has been well described (69-71, 710). However, the neonatal period is in 100 many respects unique in regard to bilirubin metabolism, as very significant elevations of UCB 101 concentrations in serum occur only exceptionally after this age. Because the actions of bilirubin 102 present something akin to a ‘Janus face’, being not only a physiologically important antioxidant; but 103 also, a toxin, particularly in the brain, it is important to understand the factors that distinguish the 104 physiology and pathophysiology of NNJ from that in the more mature organism (445). Although NNJ 105 has been described in medical literature for centuries, the recognition that severely jaundiced infants 106 are at risk for neurotoxicity is more recent. In 1904, the German pathologist Georg Schmorl described 107 the bilirubin-staining pattern and neuropathological findings in brains from infants who had died 108 with severe jaundice and coined the term ‘kernicterus’ (German for ‘jaundice of the basal ganglia’) 109 (588). Descriptions of infants who survived severe NNJ with neurologic sequelae soon followed (44, 110 262). 111 Here we review our current understanding of bilirubin chemistry and 112 physiology/pathophysiology with particular reference to NNJ. Many phenomena which may appear 113 less interesting for the mature organism turn out to be important for an infant with significant NNJ. 114 Thus, bilirubin structure, solubility, and isomerization are all important in the pathophysiology of 115 kernicterus as well as in the therapies we employ to treat jaundiced infants. The balance between 116 the dual roles of bilirubin as an antioxidant and toxin is imperfectly understood (445). Because 117 bilirubin production is a potential target for therapeutic intervention, a more detailed understanding 118 of its molecular processes is needed (221, 487, 610, 713). The genetics of hepatic processing and 119 excretion of bilirubin as well as the molecular mechanisms of intestinal handling, may hold the keys 7 120 to predicting an infant’s risk for developing significant NNJ (420, 689, 692, 732). There are many 121 theories that attempt to explain the mechanisms for bilirubin entry into and processing by the brain, 122 the differential sensitivity to bilirubin neurotoxicity both on the individual and cellular levels, and the 123 ‘basic mechanism of bilirubin neurotoxicity’, if indeed there is only one (305). Neuroprotection has in 124 recent years been developed for asphyxia-related brain damage in the newborn and may be a 125 promising area for NNJ research. Drug treatment has been promising both in vitro as well as in in vivo 126 animal experiments, but is held back by concerns for toxicity (168, 233, 418, 557). Theoretically, the 127 polar bilirubin photoisomers should be less toxic and perhaps also cross the blood-brain barrier (BBB) 128 less easily than the predominant IXα(Z,Z) isomer, but experimental support is needed (304). Thus, the 129 challenges involved in NNJ research remain a fertile field for the inquisitive mind. 130 II. BILIRUBIN IN THE BODY (FIGURE 1) 131 A. Bilirubin Chemistry 132 Bilirubin is formed in the reticuloendothelial system through the catabolism of heme. Hemoglobin 133 (Hb) is the main source (80%–85%), but other heme-containing molecules (myoglobin, cytochrome, 134 peroxidase, catalase) also contribute (70, 522). In hemolytic anemias erythropoiesis increases 135 several-fold, and an even higher proportion of heme is derived from senescing red blood cells (RBCs) 136 (71). Liver production of heme was estimated to contribute 13%–23% to the body’s total production 137 (84). The relative fraction of non-Hb heme may increase in conditions such as porphyria, 138 protoporphyria, and lead poisoning (71). 139 In healthy humans, bilirubin production was estimated at 3.5–4.0 mg/kg body weight 140 (BW)/day (69, 353), but in newborn infants it is twice as high – 8.5±2.3 mg/kg BW/day (444). 141 Increased bilirubin levels or ‘hyperbilirubinemia’ in the body are measured as total serum or plasma 142 bilirubin (TSB) by spectrophotometry or co-oximetry, or in skin by transcutaneous bilirubinometry 143 (TcB). Once bilirubin concentrations exceed certain levels, it can be visually detected as ‘jaundice’. In 144 humans, jaundice predominantly develops during the first week of life (transitional period) in 60%– 145 80% of healthy newborn infants when hepatic bilirubin metabolism mechanisms are not fully mature 8 146 (75). The risk for bilirubin neurotoxicity explains why treatment to reduce TSB levels is so important 147 in neonatal medicine (491). After the first 2 weeks of life, jaundice can sometimes be due to hepatic 148 or bile duct disease, which causes accumulation of conjugated bilirubin (glucuronic acid-bound 149 bilirubin). Rare inherited variants of bilirubin excretion and conjugation, such as Gilbert syndrome, 150 Crigler-Najjar syndrome types I and II, Rotor syndrome, Dubin-Johnson syndrome, Aagenæs 151 syndrome, and several other rare inherited and/or metabolic disorders, may cause jaundice after the 152 newborn period. 153 1. Bilirubin structure 154 The chemical structure of bilirubin was defined in 1937 by Fischer and Orth (215) as a tetrapyrrol 155 with a close relationship to Hb and its successful synthesis was reported in 1942 (FIGURE 2A) (216).
Load more

Recommended publications
  • Cerebrospinal Fluid in Critical Illness
    Cerebrospinal Fluid in Critical Illness B. VENKATESH, P. SCOTT, M. ZIEGENFUSS Intensive Care Facility, Division of Anaesthesiology and Intensive Care, Royal Brisbane Hospital, Brisbane, QUEENSLAND ABSTRACT Objective: To detail the physiology, pathophysiology and recent advances in diagnostic analysis of cerebrospinal fluid (CSF) in critical illness, and briefly review the pharmacokinetics and pharmaco- dynamics of drugs in the CSF when administered by the intravenous and intrathecal route. Data Sources: A review of articles published in peer reviewed journals from 1966 to 1999 and identified through a MEDLINE search on the cerebrospinal fluid. Summary of review: The examination of the CSF has become an integral part of the assessment of the critically ill neurological or neurosurgical patient. Its greatest value lies in the evaluation of meningitis. Recent publications describe the availability of new laboratory tests on the CSF in addition to the conventional cell count, protein sugar and microbiology studies. Whilst these additional tests have improved our understanding of the pathophysiology of the critically ill neurological/neurosurgical patient, they have a limited role in providing diagnostic or prognostic information. The literature pertaining to the use of these tests is reviewed together with a description of the alterations in CSF in critical illness. The pharmacokinetics and pharmacodynamics of drugs in the CSF, when administered by the intravenous and the intrathecal route, are also reviewed. Conclusions: The diagnostic utility of CSF investigation in critical illness is currently limited to the diagnosis of an infectious process. Studies that have demonstrated some usefulness of CSF analysis in predicting outcome in critical illness have not been able to show their superiority to conventional clinical examination.
    [Show full text]
  • CYP2A6) by P53
    Transcriptional Regulation of Human Stress Responsive Cytochrome P450 2A6 (CYP2A6) by p53 Hao Hu M.Biotech. (Biotechnology) 2012 The University of Queensland B.B.A. 2009 University of Electronic Science and Technology of China B.Sc. (Pharmacy) 2009 University of Electronic Science and Technology of China A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2016 School of Medicine ABSTRACT Human cytochrome P450 (CYP) 2A6 is highly expressed in the liver and the encoding gene is regulated by various stress activated transcription factors, such as the nuclear factor (erythroid-derived 2)-like 2 (Nrf-2). Unlike the other xenobiotic metabolising CYP enzymes (XMEs), CYP2A6 only plays a minor role in xenobiotic metabolism. The CYP2A6 is highly induced by multiple forms of cellular stress conditions, where XMEs expression is normally inhibited. Recent findings suggest that the CYP2A6 plays an important role in regulating BR homeostasis. A computer based sequence analysis on the 3 kb proximate CYP2A6 promoter revealed several putative binding sites for p53, a protein that mediates regulation of antioxidant and apoptosis pathways. In this study, the role of p53 in CYP2A6 gene regulation is demonstrated. The site closest to transcription start site (TSS) is highly homologous with the p53 consensus sequence. The p53 responsiveness of this site was confirmed by transfections with various stepwise deleted of CYP2A6-5’-Luc constructs containing the putative p53RE. Deletion of the putative p53RE resulted in a total abolishment of p53 responsiveness of CYP2A6 promoter. Specific binding of p53 to the putative p53RE was detected by electrophoresis mobility shift assay.
    [Show full text]
  • Characterisation of Bilirubin Metabolic Pathway in Hepatic Mitochondria Siti Nur Fadzilah Muhsain M.Sc
    Characterisation of Bilirubin Metabolic Pathway in Hepatic Mitochondria Siti Nur Fadzilah Muhsain M.Sc. (Medical Research) 2005 Universiti Sains Malaysia Postgrad. Dip. (Toxicology) 2003 University of Surrey B.Sc.(Biomed. Sc.) 2000 Universiti Putra Malaysia A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2014 School of Medicine ABSTRACT Bilirubin (BR), a toxic waste product of degraded haem, is a potent antioxidant at physiological concentrations. To achieve the maximum benefit of BR, its intracellular level needs to be carefully regulated. A system comprising of two enzymes, haem oxygenase-1 (HMOX1) and cytochrome P450 2A5 (CYP2A5) exists in the endoplasmic reticulum (ER), responsible for regulating BR homeostasis. This system is induced in response to oxidative stress. In this thesis, oxidative stress caused accumulation of these enzymes in mitochondria — major producers and targets of reactive oxygen species (ROS) — is demonstrated. To understand the significance of this intracellular targeting, properties of microsomal and mitochondrial BR metabolising enzymes were compared and the capacity of mitochondrial CYP2A5 to oxidise BR in response to oxidative stress is reported. Microsomes and mitochondrial fractions were isolated from liver homogenates of DBA/2J mice, administered with sub-toxic dose of pyrazole, an oxidant stressor. The purity of extracted organelles was determined by analysing the expressions and activities of their respective marker enzymes. HMOX1 and CYP2A5 were significantly increased in microsomes and even more so in mitochondria in response to pyrazole-induced oxidative stress. By contrast, the treatment did not increase either microsomes or mitochondrial Uridine-diphosphate-glucuronosyltransferase 1A1 (UGT1A1), the sole enzyme that catalyses BR elimination through glucuronidation.
    [Show full text]
  • Dissertation
    Dissertation Submitted to the Combined Faculties for the Natural Sciences and for Mathematics of the Ruperto-Carola University of Heidelberg, Germany for the Degree of Doctor of Natural Sciences Presented by Ann-Cathrin Hofer (M.Sc.) Born in Heidelberg, Germany Oral Examination: 12th of September 2016 Regulatory T cells protect the neonatal liver and secure the hepatic circadian rhythm Referees 1st Referee: Prof. Dr. Peter Angel 2nd Referee: Dr. Markus Feuerer This dissertation was performed and written during the period from November 2012 to May 2016 in the German Cancer Research Center (DKFZ) under the supervision of Prof. Dr. Peter Angel and direct supervision of Dr. Markus Feuerer. The dissertation was submitted to the Combined Faculties for the Natural Sciences and for Mathematics of the Ruperto-Carola University of Heidelberg, Germany in June 2016. German Cancer Research Center (DKFZ) Immune Tolerance (D100) Im Neuenheimer Feld 280 69120 Heidelberg, Germany I II Confirmation Hereby, I confirm that I have written this thesis independently, using only the results of my investigation unless otherwise stated. Furthermore, I declare that I have not submitted this thesis for a degree to any other academic or similar institution. Parts of this dissertation have been submitted for publishing: Regulatory T cells protect the liver early in life and safeguard the hepatic circadian rhythm Ann-Cathrin Hofer, Thomas Hielscher, David M. Richards, Michael Delacher, Ulrike Träger, Sophia Föhr, Artyom Vlasov, Marvin Wäsch, Marieke Esser, Annette Kopp-Schneider, Achim Breiling, Frank Lyko, Ursula Klingmüller, Peter Angel, Jakub Abramson, Jeroen Krijgsveld & Markus Feuerer Parts of the experiments in this dissertation were performed in collaboration with other research groups as follows: CG methylation analysis with the 454 pyrosequencing technology: Division of Epigenetics, DKFZ, Heidelberg Dr.
    [Show full text]
  • Basic Skills in Interpreting Laboratory Data, 5Th Edition
    CHAPTER 1 DEFINITIONS AND CONCEPTS KAREN J. TIETZE This chapter is based, in part, on the second edition chapter titled “Definitions and Concepts,” which was written by Scott L. Traub. Objectives aboratory testing is used to detect disease, guide treatment, monitor response Lto treatment, and monitor disease progression. However, it is an imperfect sci­ ence. Laboratory testing may fail to identify abnormalities that are present (false After completing this chapter, negatives [FNs]) or identify abnormalities that are not present (false positives, the reader should be able to [FPs]). This chapter defines terms used to describe and differentiate laboratory • Differentiate between accuracy tests and describes factors that must be considered when assessing and applying and precision laboratory test results. • Distinguish between quantitative, qualitative, and semiqualitative DEFINITIONS laboratory tests Many terms are used to describe and differentiate laboratory test characteristics and • Define reference range and identify results. The clinician should recognize and understand these terms before assessing factors that affect a reference range and applying test results to individual patients. • Differentiate between sensitivity and Accuracy and Precision specificity, and calculate and assess Accuracy and precision are important laboratory quality control measures. Labora­ these parameters tories are expected to test analytes with accuracy and precision and to document the • Identify potential sources of quality control procedures. Accuracy of a quantitative assay is usually measured in laboratory errors and state the terms of an analytical performance, which includes accuracy and precision. Accuracy impact of these errors in the is defined as the extent to which the mean measurement is close to the true value.
    [Show full text]
  • Ascites and Related Disorders
    AscitesAscites andand RelatedRelated DisordersDisorders LuisLuis S.S. Marsano,Marsano, MDMD ProfessorProfessor ofof MedicineMedicine DirectorDirector ofof HepatologyHepatology UniversityUniversity ofof LouisvilleLouisville CausesCauses ofof AscitesAscites Malignant Neoplasia 10% Cardiac Insufficiency 3% Tuberculous Peritonitis Chronic hepatic 2% disease Nephrogenic 81% a scite s (dia lysis) 1% Pancreatic ascites 1% Biliary ascites 1% Others 1% PathophysiologyPathophysiology ofof CirrhoticCirrhotic AscitesAscites Hepatic sinusoidal pressure Activation of hepatic baroreceptors Compensated Peripheral arterial vasodilation with hypervolemia, (normal renin, aldosterone, vasopressin, or norepinephrine) Peripheral arterial vasodilation (“underfilling”) Decompensated Neurally mediated Na+ retention, (with elevated renin, aldosterone, vasopressin, or norepinephrine) ClassificationClassification ofof AscitesAscites SerumSerum--ascitesascites albuminalbumin gradientgradient (SAAG)(SAAG) SAAGSAAG (g/dl)(g/dl) == albuminalbumins –– albuminalbumina GradientGradient >>1.11.1 g/dlg/dl == portalportal hypertensionhypertension Serum globulin > 5 g/dl:: – SAAG correction = (SAAG mean)(0.21+0.208 serum globulin g/dl) AscitesAscites withwith HighHigh SAAGSAAG >>1.11.1 g/dlg/dl == portalportal hypertensionhypertension Cirrhosis Alcoholic Hepatitis Cardiac ascites Massive hepatic metastasis Fulminant hepatic failure Budd-Chiari syndrome Portal vein thrombosis Veno-occlusive disease Acute fatty liver of pregnancy Myxedema Mixed ascites LowLow SAAGSAAG <1.1<1.1
    [Show full text]
  • Solarbio Catalogue with PRICES
    CAS Name Grade Purity Biochemical Reagent Biochemical Reagent 75621-03-3 C8390-1 3-((3-Cholamidopropyl)dimethylammonium)-1-propanesulfonateCHAPS Ultra Pure Grade 1g 75621-03-3 C8390-5 3-((3-Cholamidopropyl)dimethylammonium)-1-propanesulfonateCHAPS 5g 57-09-0 C8440-25 Cetyl-trimethyl Ammonium Bromide CTAB High Pure Grade ≥99.0% 25g 57-09-0 C8440-100 Cetyl-trimethyl Ammonium Bromide CTAB High Pure Grade ≥99.0% 100g 57-09-0 C8440-500 Cetyl-trimethyl Ammonium Bromide CTAB High Pure Grade ≥99.0% 500g E1170-100 0.5M EDTA (PH8.0) 100ml E1170-500 0.5M EDTA (PH8.0) 500ml 6381-92-6 E8030-100 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 100g 6381-92-6 E8030-500 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 500g 6381-92-6 E8030-1000 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 1kg 6381-92-6 E8030-5000 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 5kg 60-00-4 E8040-100 Ethylenediaminetetraacetic acid EDTA Ultra Pure Grade ≥99.5% 100g 60-00-4 E8040-500 Ethylenediaminetetraacetic acid EDTA Ultra Pure Grade ≥99.5% 500g 60-00-4 E8040-1000 Ethylenediaminetetraacetic acid EDTA Ultra Pure Grade ≥99.5% 1kg 67-42-5 E8050-5 Ethylene glycol-bis(2-aminoethylether)-N,N,NEGTA′,N′-tetraacetic acid Ultra Pure Grade ≥97.0% 5g 67-42-5 E8050-10 Ethylene glycol-bis(2-aminoethylether)-N,N,NEGTA′,N′-tetraacetic acid Ultra Pure Grade ≥97.0% 10g 50-01-1 G8070-100 Guanidine Hydrochloride Guanidine HCl ≥98.0%(AT) 100g 50-01-1 G8070-500 Guanidine Hydrochloride Guanidine HCl ≥98.0%(AT) 500g 56-81-5
    [Show full text]
  • Hyperchloremia – Why and How
    Document downloaded from http://www.elsevier.es, day 23/05/2017. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. n e f r o l o g i a 2 0 1 6;3 6(4):347–353 Revista de la Sociedad Española de Nefrología www.revistanefrologia.com Brief review Hyperchloremia – Why and how Glenn T. Nagami Nephrology Section, Department of Medicine, VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, United States a r t i c l e i n f o a b s t r a c t Article history: Hyperchloremia is a common electrolyte disorder that is associated with a diverse group of Received 5 April 2016 clinical conditions. The kidney plays an important role in the regulation of chloride concen- Accepted 11 April 2016 tration through a variety of transporters that are present along the nephron. Nevertheless, Available online 3 June 2016 hyperchloremia can occur when water losses exceed sodium and chloride losses, when the capacity to handle excessive chloride is overwhelmed, or when the serum bicarbonate is low Keywords: with a concomitant rise in chloride as occurs with a normal anion gap metabolic acidosis Hyperchloremia or respiratory alkalosis. The varied nature of the underlying causes of the hyperchloremia Electrolyte disorder will, to a large extent, determine how to treat this electrolyte disturbance. Serum bicarbonate Published by Elsevier Espana,˜ S.L.U. on behalf of Sociedad Espanola˜ de Nefrologıa.´ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
    [Show full text]
  • Routine Cerebrospinal Fluid (CSF) Analysis
    CHAPTER4 Routine cerebrospinal fluid (CSF) analysis a b a ) F. Deisenhammer, A. Bartos, R. Egg, Albumin CSF/serum ratio (Qalb should be pre- N. E. Gilhus,c G. Giovannoni,d S. Rauer,e ferred to total protein measurement and normal F. Sellebjergf upper limits should be related to patients’ age. Elevated Qalb is a non-specific finding but occurs mainly in bacterial, cryptococcal, and tubercu- Background A great variety of neurological diseases lous meningitis, leptomingeal metastases as well require investigation of the cerebrospinal fluid as acute and chronic demyelinating polyneu- (CSF) to prove the diagnosis or to rule out relevant ropathies. differential diagnoses. Pathological decrease of the CSF/serum glu- cose ratio or an increase in lactate concentration Objectives To evaluate the theoretical background indicates bacterial or fungal meningitis or lep- and provide guidelines for clinical use in rou- tomeningeal metastases. tine CSF analysis including total protein, albumin, Intrathecal immunoglobulin G synthesis is best immunoglobulins, glucose, lactate, cell count, demonstrated by isoelectric focusing followed by cytological staining, and investigation of infec- specific staining. tious CSF. Cellular morphology (cytological staining) should be evaluated whenever pleocytosis is found or Methods Systematic Medline search for the above leptomeningeal metastases or pathological bleed- mentioned variables. Review of appropriate publi- ing is suspected. Computed tomography-negative cations by one or more of the task force members. intrathecal bleeding should be investigated by Grading of evidence and recommendations was bilirubin detection. based on consensus by all task force members. Introduction CSF should be analysed immediately after collec- tion. If storage is needed 12 ml of CSF should The cerebrospinal fluid (CSF) is a dynamic, be partitioned into three to four sterile tubes.
    [Show full text]
  • The Pathophysiology of 'Happy' Hypoxemia in COVID-19
    Dhont et al. Respiratory Research (2020) 21:198 https://doi.org/10.1186/s12931-020-01462-5 REVIEW Open Access The pathophysiology of ‘happy’ hypoxemia in COVID-19 Sebastiaan Dhont1* , Eric Derom1,2, Eva Van Braeckel1,2, Pieter Depuydt1,3 and Bart N. Lambrecht1,2,4 Abstract The novel coronavirus disease 2019 (COVID-19) pandemic is a global crisis, challenging healthcare systems worldwide. Many patients present with a remarkable disconnect in rest between profound hypoxemia yet without proportional signs of respiratory distress (i.e. happy hypoxemia) and rapid deterioration can occur. This particular clinical presentation in COVID-19 patients contrasts with the experience of physicians usually treating critically ill patients in respiratory failure and ensuring timely referral to the intensive care unit can, therefore, be challenging. A thorough understanding of the pathophysiological determinants of respiratory drive and hypoxemia may promote a more complete comprehension of a patient’sclinical presentation and management. Preserved oxygen saturation despite low partial pressure of oxygen in arterial blood samples occur, due to leftward shift of the oxyhemoglobin dissociation curve induced by hypoxemia-driven hyperventilation as well as possible direct viral interactions with hemoglobin. Ventilation-perfusion mismatch, ranging from shunts to alveolar dead space ventilation, is the central hallmark and offers various therapeutic targets. Keywords: COVID-19, SARS-CoV-2, Respiratory failure, Hypoxemia, Dyspnea, Gas exchange Take home message COVID-19, little is known about its impact on lung This review describes the pathophysiological abnormal- pathophysiology. COVID-19 has a wide spectrum of ities in COVID-19 that might explain the disconnect be- clinical severity, data classifies cases as mild (81%), se- tween the severity of hypoxemia and the relatively mild vere (14%), or critical (5%) [1–3].
    [Show full text]
  • Junbai Li Editor Supramolecular Chemistry of Biomimetic Systems Supramolecular Chemistry of Biomimetic Systems Junbai Li Editor
    Junbai Li Editor Supramolecular Chemistry of Biomimetic Systems Supramolecular Chemistry of Biomimetic Systems Junbai Li Editor Supramolecular Chemistry of Biomimetic Systems 123 Editor Junbai Li Institute of Chemistry, Chinese Academy of Sciences Beijing China ISBN 978-981-10-6058-8 ISBN 978-981-10-6059-5 (eBook) DOI 10.1007/978-981-10-6059-5 Library of Congress Control Number: 2017949116 © Springer Nature Singapore Pte Ltd. 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer Nature Singapore Pte Ltd.
    [Show full text]
  • Pathophysiology in Pre-Clerkship Curriculum Pathophysiology
    Pathophysiology In Pre-Clerkship Curriculum Pathophysiology • The study of the biologic and physical manifestations of disease as they correlate with the underlying abnormalities and physiologic disturbances. Pathophysiology does not deal directly with the treatment of disease. Rather, it explains the processes within the body that result in the signs and symptoms of a disease. USMLE Steps 1 & 2 • Do not report separate pathophysiology score 2018 NBME Pathology Subject Exam 2017 NBME Pathology Subject Exam Pathophysiology in Pre- Clerkship Curriculum • Minor – Doctoring I – case-based learning – Anatomy – Cellular & Molecular Medicine – Genetics – Cell & Tissue Biology – Physiology – Introduction to Clinical Psychiatry – Microbiology – Neuroscience Pathophysiology in Pre- Clerkship Curriculum • Major – Doctoring II – Practice of Medicine – Pathology – Pharmacology Practice of Medicine • First course objective – Integrate, review, and apply basic science pathophysiology to clinical cases Practice of Med/Doctoring II • Pathophysiology of pelvic inflammatory disease/tubo-ovarian abscess • Pathophysiology of Diabetic peripheral neuropathy • Pathophysiology of pancreatitis • Pathophysiology of diarrhea • Pathophysiology of pneumonia • Pathophysiology of chest pain/acute coronary syndrome Practice of Med/Doctoring II • Pathophysiology of ecchymoses & purpura • Pathophysiology of mysathenia gravis (dropped in 2019) • Renal failure pathophysiology (dropped in 2019) • DKA pathophysiology • Anemia pathophysiology • Discussed in sim lab cases: pathophysiology
    [Show full text]